Navigation Links
Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
Date:9/14/2010

BALTIMORE, Sept. 14 /PRNewswire/ -- Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARC-4558 for the treatment of pain associated with Painful Diabetic Neuropathy (PDN). ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration. Arcion recently announced positive top-line results from a Phase 2b double-blind, randomized, placebo-controlled clinical trial of ARC-4558 in adult patients with PDN. The Company also recently held an End of Phase 2 meeting with the FDA and the ARC-4558 program is now poised to enter Phase 3 studies.

The Fast Track program of the FDA is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track designated drugs typically qualify for priority review, thereby expediting the FDA review process.

"This Fast Track designation is an important recognition by the FDA of the potential for ARC-4558 to address the unmet need for better agents to control the pain involved in PDN, a serious condition," said James Campbell, M.D., Chief Executive Officer of Arcion. "Having the Fast Track designation will be of great value to Arcion as we work with the FDA to come to an agreement on the final Phase 3 program, as well as open the way to a potential priority review."  

About ARC-4558

ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride (HCL) for topical administration to the painful area in order to manage the neuropathic pain associated with painful diabetic neuropathy (PDN).  Topical clonidine, thr
'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
2. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
3. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
4. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
5. Halozyme Therapeutics Announces Public Offering of Common Stock
6. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
7. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
8. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
9. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
10. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is ... destroy faulty electrical pathways from sections of the ... as cardiac arrhythmias). Cardiac arrhythmias can be of ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:7/23/2014)... have been focused on the regions of the coding ... form of amino acids thus proteins. But just before ... which controls the expression and activity of the adjacent ... role exerted such DNA fragment in tumor development. ... in collaboration with the group of Manel Esteller, Director ...
(Date:7/23/2014)... therapy combining salmon fibrin injections into the spinal cord ... restored voluntary motor function impaired by spinal cord injury, ... , In a study on rodents, Gail Lewandowski and ... developmental clock in a molecular pathway critical to the ... scaffold so that neuronal axons at the injury site ...
(Date:7/23/2014)... 23, 2014 This report defines and ... (Asia-Pacific, Europe, the Middle East & Africa, and Americas) ... and geography with analysis and forecasts of the global ... grow from over $10 billion in 2014 to nearly ... 5%. , browse 49 Market Tables and 10 ...
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... (HealthDay News) -- Children and teens who lose a parent ... adulthood, a new study suggests. People who were children ... greater risk of death during the study period than those ... to the report. Although the study found an association ... premature death, it wasn,t designed to prove cause-and-effect. Also, ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2
... curb dementia, researchers say, , , TUESDAY, Nov. 18 (HealthDay ... new research suggests that the herb ginkgo biloba won,t ... found that giving a standardized dose of ginkgo biloba ... the incidence rate of dementia or Alzheimer,s disease," said ...
... of allergic reactions, other problems have surfaced with these ... - American women who turn to cosmetic treatments called ... as to the health risks these products pose, an ... recommended Tuesday. , The panel of independent experts urged ...
... , RESTON, Va., Nov. 18 ... D prescription drug benefit in 2008 are satisfied with their ... nationwide education and advocacy group for older Americans. , ... Similar surveys conducted over the last year found the same ...
... now the only over the counter treatment for chronic and acute ... prevents contamination of wounds and speeds up the healing process. ... ... the development of Wound-Be-Gone, all skin injuries, especially large, chronic wounds, ...
... 18 (Nasdaq: WHRTD ) World,Heart Corporation ... 2008, the Company received a letter from The NASDAQ ... with Marketplace,Rule 4310(c)(4) (the "Minimum Bid Price Rule") and ... at $1.00 per share or greater for at least ...
... WASHINGTON, Nov. 18 Over 2 million low-income Medicare,beneficiaries ... in,January. Changes to the 2009 Medicare Part D plans ... premiums they cannot afford or limit,access to their prescriptions, ... Law Center (NSCLC). Part D open enrollment runs from ...
Cached Medicine News:Health News:Ginkgo No Shield Against Alzheimer's 2Health News:Ginkgo No Shield Against Alzheimer's 3Health News:Wrinkle Fillers Need Better Label Warnings: FDA Panel 2Health News:Wrinkle Fillers Need Better Label Warnings: FDA Panel 3Health News:New Survey Shows Seniors Overwhelmingly Satisfied With Medicare Part D 2Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 2Health News:A Revolution in Wound Healing, Wound-Be-Gone Now the Only Over the Counter Treatment for Chronic and Acute Wounds 3Health News:WorldHeart Regains Compliance With the Minimum Bid Price Rule 2Health News:2009 Medicare Part D Premiums to Rise Dramatically: Over 2 Million Low Income Beneficiaries At Risk 2
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... SL1 developed by STORZ MEDICAL is the ... in the field of kidney stone lithotripsy ... requirements to be met by orthopaedic apparatus ... been outlined above. The MINILITH SL1 is ...
... transportable, the Dornier Compact Delta lithotripsy system features ... patient. The systems shock source and C-arm are ... avoid the risk of misalignment. The therapy head ... its motorized lateral and horizontal movement and can ...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
Medicine Products: